

****Published March 2018****

MarketVIEW: mRNA vaccines (infectious diseases) (CAT: VAMV079)

Product Name	:	MarketVIEW: mRNA vaccines (infectious diseases)
Description	:	mMRNA vaccines: landscape overview and pipeline analysis
Contents	:	Executive presentation (105 slides, .pdf) + 1 MS Excel workbook (.xls)
Therapeutic Area	:	Novel vaccine technologies
Publication date	:	March 2018
Catalogue No	:	VAMV079

Background

'**Nucleic acid-based therapeutics**', based on mRNA, are a group of technologies with potential applications in vaccination for cancer, infectious diseases and diseases requiring protein replacement therapy. Improvements in mRNA formulation and delivery using lipid nanoparticle and cationic nanoparticle encapsulation have overcome early issues with stability and complex dendritic cell (DC) loading techniques. Landmark studies have shown that directly injected encapsulated mRNA is both safe and immunogenic triggering humoral and cellular immune responses in healthy and cancer patients.

mRNA vaccines are potentially disruptive because they provide some critical advantages over existing vaccine antigen approaches.

This **MarketVIEW** product consists of a detailed Executive presentation (~105 .pdf slides) and MS-Excel workbook (.xls) which gives a comprehensive overview of mRNA technologies and their potential application in the prophylactic and therapeutic setting for cancer and infectious diseases indications. An **R&D pipeline analysis** is provided which details all current mRNA candidates at clinical stages. Major companies and alliances are outlined with a focus on each individual program (infectious diseases). Importantly, drawing upon our VacZine Analytics research portfolio, a strategic analysis is included whereby opportunities associated with mRNA technologies are contrasted with the competitive threat level should a new vaccine progress to licensure. This report is ideal for any client wishes to understand the potential significance of this emerging field.

Methodology

VacZine Analytics has closely monitored all significant source material pertaining to mRNA vaccines technologies, vaccine development and competitive environment. Source materials used are literature articles, government websites, medical bodies and associations, conference proceedings, news articles, expert comment etc.

PRODUCT CONTENTS:

Published March 2018 (CAT No: VAMV079)

****This product is composed of [one Excel workbook \(.xls\)](#)¹ and [an Executive presentation \(.pdf\)](#)²

Authors note

Table of Contents

Executive summary

[Section] mRNA vaccines – Background

16 slides

[Section] mRNA vaccines – R&D pipeline analysis

mRNA vaccines: pipeline analysis methodology

mRNA pipeline analysis: number of clinical trials

mRNA pipeline analysis: industry vs non-industry clinical trials

mRNA pipeline analysis: cancer indications in clinical trials

mRNA pipeline analysis: infectious disease indications in clinical trials

mRNA pipeline analysis: clinical studies by phase

mRNA pipeline analysis: clinical studies by intervention type

mRNA pipeline analysis: clinical studies by initiation date

mRNA pipeline analysis: key companies with mRNA vaccines in clinical studies

[Section] mRNA vaccines - R&D pipeline analysis of key companies – Infectious diseases

Company 1

Company 2

Company 3

Company 4

Additional companies

Appendices: Back-up and source material

Bibliography

About **VacZine Analytics**

Disclaimer

Slide number = 105 (.pdf)

Model worksheet number 5 (.xls)

Bibliography = 132 references



SNAPSHOT

¹ Workbook contents available on request (.xls)

² Presentation titles may apply to more than one slide (.pdf form only)

PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- FULL PRODUCT (All deliverables) - USD **\$7,995**/ GBP **£5,700**[#] (region license)*

[#] Indicative company rate only. Prevailing rate applied to date of transaction.

*A region is North America, Europe or ROW

For orders in the UK, VAT at 20.0% will be added to final invoice total
Biotech and "not for profit" rates are available upon request

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com
This report can also be purchased online. Please review the **TERMS** and **CONDITIONS** of purchase.



TERMS and CONDITIONS:

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. All Rights Reserved. This finished research product is a licensed product. It may not be reproduced, stored in a retrieval system or transmitted in any form without the written permission of the Company **VacZine Analytics** (a division of Assay Advantage Ltd).
2. The license granted by the Company to the Client will be non-exclusive, non-transferable and should only be used for the Client business purposes at the agreed Client sites/location in accordance with this agreement. The Client will have no ownership rights over the research product.
3. Invoicing will **100%** after submission of the deliverables (.pdf) and (.xls) to the Client.
4. If not purchased online invoices are payable within **thirty days** of the invoice date.
5. All proposals are quoted in **\$USD dollars, or £GBP or €euro** and invoices are to be settled in the same currency.
6. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the research product listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company’s employees, and agents with the performance of the Company’s obligations to achieve satisfactory completion of the project and approved in writing by the Client.
7. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
8. Please also refer to Master **TERMS and CONDITIONS** available upon request.

VacZine Analytics

a division of Assay Advantage Ltd
Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 813155
E-mail: info@vacZine-analytics.com

About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information, please visit our website www.vacZine-analytics.com

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics (R) and “the spiral logo” are UK Registered Trademarks, 2009